



CONTROLLED TRIAL OF HIGH-RISK CORONARY INTERVENTION WITH PERCUTANEOUS LEFT VENTRICULAR UNLOADING

LONDON SCHOOL of HYGIENE & TROPICAL MEDICINE



CLINICAL TRIALS UNIT

Working Practice Document: RANDOMISATION		
CURRENT VERSION WPD: CHIP-BCIS3 WPD/03/02		
Current version date:	07 Jun 2024	
Review date:	07 Jun 2027	
Author:	Laura Van Dyck (Data Manager)	
Reviewed by:	Steven Robertson (Senior Data Manager)	
Approved by:	Matt Kwok (Trial Manager)	

Revision chronology:		
Version number	Effective date	Reason for change
1	18 Jun 2021	Scheduled review; updated section 2 (to include Randomisation accounts) & added in section 5.2 (randomised in error)
2	07 Jun 2024	

Table of Contents

1. Purpose of this document	3
2. Accessing the system	4
3. Passwords	6
3.1 Forgotten passwords	6
3.2 Changing a password	6
4. Auto time-out	7
5. Randomisation Procedure	8
5.1 Randomising patients	8
5.2 Patients randomised in error	10
6. Contacting the CHIP-BCIS3 CTU	11

1. Purpose of this document

The purpose of this document is to give an overview of the online randomisation system for the CHIP-BCIS3 trial: **C**ontrolled trial of **H**igh-risk coronary **I**ntervention with **P**ercutaneous left ventricular unloading.

2. Accessing the system

The only staff that will be granted access to the randomisation system from the sites are the staff undertaking randomisation procedures. They will be issued 'Investigator' or 'Randomisation' accounts as required, which allow them to randomise patients, view the randomisation data for their site, and generate queries. In addition 'Investigator' accounts enable delegated site personnel to edit, add and view eCRF forms as well as upload attachments. These account types may be provided to a range of staff (e.g. research nurses, pharmacists, or clinicians) as needed.

Staff at the London School of Hygiene and Tropical Medicine (LSHTM) Clinical Trials Unit (CTU) will have 'Administrator' accounts, which allow them to create accounts and view the data for all sites.

Access to the randomisation system is via <https://www.sealedenvelope.com/access/> and users must log in with their email address and password before access is granted (see Figure 1).

Note: the screenshots shown below are taken from the testing site which uses dummy data.

Figure 1:

Access

Please log in

To log in you must enter your registered email address and password.

Email address:

Password:

[Log in](#)

[Forgot your password?](#)

Programs and data held on this server are PRIVATE PROPERTY. Unauthorised access is prohibited and is contrary to the Computer Misuse Act 1990, which may result in criminal offences and a claim for damages. Users are reminded to keep their log in details confidential and never to share them with any other person. Users must contact Sealed Envelope Ltd immediately if they become aware of any suspicious activity.


2021-05-28T09:15:45+00:00

If a user does not have an account, or provides an incorrect password, they will not be allowed access. Investigator and Randomisation accounts will be set up by a member of the CTU team. This will only occur once the appropriate training has taken place and the training and delegation logs have been signed.

When a user has logged in their name and unique user ID is always shown at the top of every page in the navigation bar.


After logging in for the first time the user will see Figure 2 (the "Access" page) and this will show a message that reads 'You have an invitation'. The user should click on this link and accept the invitation, this will add the trial to their access page.

Figure 2:



The user should then click on the “Access with role” link to enter the study, as shown in Figure 3.

Figure 3:



Once a user has finished using the database application, it is good practice to log out. This is particularly important if the user is using a shared computer or a computer that is not their own. To log out, click on the “Logout” link in the navigation bar at the top of the page.

Note: To comply with good clinical practice (GCP), it is very important that users do not share accounts or allow others to access their accounts, even temporarily. If a user has forgotten their details or is unable to log in, please refer to section 3 for more information.

3. Passwords

3.1 Forgotten passwords

Forgotten passwords can be reset by users by clicking the “Forgot your password?” link on the login page. This can only be done if they have set up a recovery email address (different to the account email address) or mobile phone number. If a user forgets their password but has not set up recovery contact details, they should contact the CHIP-BCIS3 CTU and the user’s password will be reset. This sends out a new password by email to the account holder.

It is highly recommended that users provide recovery details on their user account.

Requests for password resets made by investigators to Sealed Envelope will be referred to the CHIP-BCIS3 CTU to ensure the validity of the request. Note: there is no way to see a user’s current password – they are stored in an encrypted format that not even Sealed Envelope* staff can decrypt.

*Sealed Envelope is the organisation responsible for developing and maintaining the CHIP-BCIS3 data management systems (<https://www.sealedenvelope.com/>).

3.2 Changing a password

If a user would like to change their password, click on the “My Account” link at the top of the screen. This link directs the user to the screen shown in Figure 4 below. To change a password it is necessary for the user to enter their existing password. New passwords must be at least 8 characters long. It is advisable to avoid using passwords that are obvious or easily guessed.

Passwords expire after 180 days, after which point a user is forced to change their password. Users with expired passwords have no access to the system except for the change password screen. From this screen it is also possible to update your email address, and add (or update) a back-up email address or mobile phone number.

Figure 4:

The screenshot shows a user account management interface. At the top, there is a navigation bar with 'Access' on the left and 'TRIALS MY ACCOUNT LOG OUT - LAURA (TEST PI, SITE 11) (ID 12330) sealed envelope' on the right. The main content is divided into two columns. The left column is titled 'My account' and contains a sub-section 'Update your details'. It includes form fields for 'Name' (filled with 'Laura Van Dyck'), 'Email address' (filled with 'laura.vandyck@shtm.ac.uk'), and 'Timezone' (set to '(GMT+00:00) UTC'). Below these is a blue callout box with a plus icon and the text: 'Add a back-up email address or mobile phone number to allow you to reset your password if you forget it'. This box contains fields for 'Back-up email address' (filled with 'me@alternative.com'), 'Country' (set to 'United Kingdom'), and 'Mobile phone number' (filled with '7000 777777'). A note below the mobile number field states: 'This number will only be used for account security purposes'. At the bottom of this section is the text: 'Confirm your current password to make changes to your account'. The right column is titled 'Change your password'. It shows the last password change date: 'You last changed your password Wed, 26 May 2021 2:48pm UTC (2 days ago)'. It has a 'Confirm your current password' field (filled with 'current password'), a 'Some password suggestions:' section with a list of words (ether, deacon, flex, rotc, xp, zealot, decree, aubrey, farce) and a 'Suggest more passwords' button, a 'Your new password' field (filled with 'new password') with a note 'Your new password must be at least 8 characters long', and a 'Confirm your new password' field (filled with 'new password again'). A blue 'Change' button is at the bottom, with a note below it: 'You cannot submit this form with a weak password'.

4. Auto time-out

After a set period of inactivity (15-20 minutes), the user is automatically logged out of the system.

5. Randomisation Procedure

5.1 Randomising patients

Randomising will be done only by the member of staff whom has been delegated this responsibility by the principal investigator as evidenced by documentation in the delegation log.

We do not mandate a specific time period between randomisation and treatment. However, we recommend that randomisation should be done as close to the PCI procedure as possible, to minimise the chance of events occurring during this time period.

To randomise a patient to the CHIP-BCIS3 trial:

1. Log in to the system (<https://www.sealedenvelope.com/access>)
2. Click the “Randomise” link on the top left hand side of the screen on the navigation bar, which will open the randomisation data entry screen
3. Use the “Randomise” screen to enter the inclusion/exclusion criteria (see Figure 5) and click “Randomise”

Figure 5:

⚠ This is a test system for your user acceptance testing. Do not enter real data!

CHIP-BCIS3 TRIALS HELP MY ACCOUNT LOG OUT - LAURA (TEST PI, SITE 11) (ID 12330 - INVESTIGATOR AT 11: SITE 11) sealed envelope

Randomise Randomisations Queries

Randomisation

Complete this form to add a new subject to Red Pill. No other forms will be accessible until this form has been entered.

Randomisation

Patient ID
Automatically generated

Month and year of birth*

Date of informed consent*
28/05/2021

Time of informed consent*

hh:mm

4. After submitting the randomisation data, the user will be asked to review it as changes will not be allowed after confirming. If you need to amend any of the details hit the “Back” button.
5. In order to complete randomisation of the patient you will have to enter your password and click “Confirm”.
6. The patient is now in the CHIP-BCIS3 trial and a pop up (Figure 6a) followed by the confirmation screen will appear (see Figure 6b). This will confirm the CHIP-BCIS3 patient ID number, randomisation details and treatment allocated.

Figure 6a:






Figure 6b:



Email confirmation

The CHIP-BCIS3 CTU and all staff with 'Investigator' and 'Randomisation' accounts at the site will be sent an email containing the CHIP-BCIS3 patient ID number and treatment allocation (see Figure 7).

Figure 7:



Following randomisation, ensure that the treatment is carried out as per the randomisation allocation.

5.2 Patients randomised in error

Patients randomised in error should be a very rare occurrence, if all the correct procedures are carried out. However, if you suspect that a patient has been randomised in error please contact the CTU as soon as possible, who will advise on how to proceed.

Scenarios where a patient would be marked as 'Randomised in error' by the CTU:

1. A second randomisation of a patient (note: the first randomised allocation must be used in this scenario)
2. A patient randomised to the wrong trial
3. A patient randomised without the agreed consent procedures in place

6. Contacting the CHIP-BCIS3 CTU

If you require help with this instruction manual please contact the CHIP-BCIS3 CTU by emailing us at chip-bcis3@LSHTM.ac.uk

The CHIP-BCIS3 CTU is based at the London School of Hygiene and Tropical Medicine (LSHTM) which is part of the University of London.